Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infection
Sign Up to like & getrecommendations! Published in 2022 at "Science Advances"
DOI: 10.1126/sciadv.abo5400
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces mild or asymptomatic COVID-19 in most cases, but some patients develop an excessive inflammatory process that can be fatal. As the NLRP3 inflammasome and additional inflammasomes are… read more here.
Keywords: drugs inhibit; identification immunomodulatory; immunomodulatory drugs; cov infection ... See more keywords
Mice no longer immune to immunomodulatory drugs.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-08-868083
Abstract: In this issue of Blood, Fink et al report that a single amino acid change in cereblon (CRBN), the direct target of thalidomide and its derivatives, confers sensitivity to immunomodulatory drugs in mice.1 read more here.
Keywords: mice longer; immunomodulatory; immune immunomodulatory; immunomodulatory drugs ... See more keywords
Clinical use of antiviral, antibiotic and immunomodulatory drugs in hospitalized COVID-19 patients: a retrospective study in Bandung, Indonesia
Sign Up to like & getrecommendations! Published in 2021 at "F1000Research"
DOI: 10.12688/f1000research.73606.1
Abstract: Background: Evidence of highly effective repurposed drugs for coronavirus disease 2019 (COVID-19) is insufficient. However, empirical therapy using antiviral, antibiotic and immunomodulatory drugs is massive. Studies evaluating the clinical use of these drugs in Indonesia… read more here.
Keywords: covid patients; clinical use; immunomodulatory drugs; antiviral antibiotic ... See more keywords
IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.3324/haematol.2019.217943
Abstract: Cereblon (CRBN), a target of immunomodulatory drugs (IMiD), forms the CRL4 E3 ubiquitin ligase (CRL4) complex with DDB1, CUL4B and ROC1. Under the influence of IMiD, CRL4 polyubiquitinates and thus depletes the transcription factors IKZF1… read more here.
Keywords: multiple myeloma; ubiquitin ligase; imid; immunomodulatory drugs ... See more keywords
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1017990
Abstract: Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide and pomalidomide are antitumor compounds that have direct tumoricidal activity and indirect effects mediated by multiple types of immune cells in the tumor microenvironment (TME). IMiDs have shown… read more here.
Keywords: cell neoplasms; cell; tumor microenvironment; immunomodulatory drugs ... See more keywords
Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.989032
Abstract: Objective: In recent years, the emergence of immunomodulatory drugs (IMiDs) has significantly improved clinical outcomes in patients with multiple myeloma (MM); however, serious adverse events (AEs) have hindered their safe clinical application. This study aimed… read more here.
Keywords: system; safety; reporting; adverse event ... See more keywords
Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13184666
Abstract: Simple Summary Due to the complex mechanism of actions, immunomodulatory drugs (IMiDs) are one of the primary drug classes used to treat multiple myeloma (MM). IMiDs are the backbone of treatment for both newly diagnosed,… read more here.
Keywords: ligase modulators; treatment; multiple myeloma; immunomodulatory drugs ... See more keywords
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa—Possibilities and Limitations
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23179716
Abstract: Hidradenitis suppurativa, also known as acne inversa, is a chronic, progressive, debilitating, recurrent inflammatory skin disease characterized by the occurrence of very severe, persistent, painful nodules, abscesses, and fistulas, most commonly found in the skin… read more here.
Keywords: hidradenitis suppurativa; treatment; acne inversa; immunomodulatory drugs ... See more keywords
Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm13040664
Abstract: Acute respiratory distress syndrome (ARDS) is intricately linked with SARS-CoV-2-associated disease severity and mortality, especially in patients with co-morbidities. Lung tissue injury caused as a consequence of ARDS leads to fluid build-up in the alveolar… read more here.
Keywords: respiratory distress; distress syndrome; syndrome ards; immunomodulatory drugs ... See more keywords
Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15091077
Abstract: Dramatic advancement has been made in recent decades to understand the basis of autoimmunity-mediated neurological diseases. These diseases create a strong influence on the central nervous system (CNS) and the peripheral nervous system (PNS), leading… read more here.
Keywords: neurological diseases; autoimmunity; current advancement; based neurological ... See more keywords